NCT01602380 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 230
- group Id
- BG001
- value
- 232
- group Id
- BG002
- value
- 462
- units
- Participants
- groups
- description
- Patients received fulvestrant (Faslodex™) 500 mg, administered as two 5 mL intramuscular injections, 1 in each buttock, at each visit on Days 0, 14 (±3), 28 (±3) and every 28 (±3) days thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive fulvestrant, also received placebo to match the anastrozole schedule (tablets, once daily).
- id
- BG000
- title
- Fulvestrant 500 mg
- description
- Patients received anastrozole (Arimidex™), administered orally as a single tablet at a dose of 1 mg/day from randomisation on Day 0 and once daily thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive anastrozole also received placebo to match the fulvestrant schedule (injections on Days 0, 14 \[±3\], 28 \[±3\] and every 28 \[±3\] days thereafter).
- id
- BG001
- title
- Anastrozole 1 mg
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 38
- spread
- 9.86
- upper Limit
- 87
- value
- 63.8
- group Id
- BG001
- lower Limit
- 36
- spread
- 10.38
- upper Limit
- 90
- value
- 63.3
- group Id
- BG002
- lower Limit
- 36
- spread
- 10.12
- upper Limit
- 90
- value
- 63.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 230
- group Id
- BG001
- value
- 232
- group Id
- BG002
- value
- 462
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 70
- title
- Asian
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 175
- group Id
- BG001
- value
- 174
- group Id
- BG002
- value
- 349
- title
- White
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 29
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The intention to treat (ITT) analysis set included all randomised patients.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 230
- group Id
- BG001
- value
- 232
- group Id
- BG002
- value
- 462
- units
- Participants
- groups
- description
- Patients received fulvestrant (Faslodex™) 500 mg, administered as two 5 mL intramuscular injections, 1 in each buttock, at each visit on Days 0, 14 (±3), 28 (±3) and every 28 (±3) days thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive fulvestrant, also received placebo to match the anastrozole schedule (tablets, once daily).
- id
- BG000
- title
- Fulvestrant 500 mg
- description
- Patients received anastrozole (Arimidex™), administered orally as a single tablet at a dose of 1 mg/day from randomisation on Day 0 and once daily thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive anastrozole also received placebo to match the fulvestrant schedule (injections on Days 0, 14 \[±3\], 28 \[±3\] and every 28 \[±3\] days thereafter).
- id
- BG001
- title
- Anastrozole 1 mg
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 38
- spread
- 9.86
- upper Limit
- 87
- value
- 63.8
- group Id
- BG001
- lower Limit
- 36
- spread
- 10.38
- upper Limit
- 90
- value
- 63.3
- group Id
- BG002
- lower Limit
- 36
- spread
- 10.12
- upper Limit
- 90
- value
- 63.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 230
- group Id
- BG001
- value
- 232
- group Id
- BG002
- value
- 462
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 36
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 70
- title
- Asian
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 175
- group Id
- BG001
- value
- 174
- group Id
- BG002
- value
- 349
- title
- White
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 29
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The intention to treat (ITT) analysis set included all randomised patients.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle